ClinicalTrials.gg
CompletedNCT04615923Updated Aug 23, 2023Results posted

HEALEY ALS Platform Trial - Regimen D Pridopidine

A Phase 2/3 interventional study of Pridopidine and Matching Placebo in Amyotrophic Lateral Sclerosis, sponsored by Merit E. Cudkowicz, MD. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-23.

Sponsored by Merit E. Cudkowicz, MD · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
163
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.

Enrollment
47th of 307
163 · median 33
Started
2020
with 28 others
Phase 2/3
18 of 440
1 open now
Registered
279th of 440
by date
Lead sponsor
9 of 440
Merit E. Cudkowicz, MD

Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 47th largest by enrollment of the 307 interventional ones that give a count, is one of 29 that started in 2020, is one of 18 in phase 2/3, and was the 279th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, or all of them as a file.
02

Study summary

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.

Regimen D will evaluate the safety and efficacy of a single study drug, pridopidine, in participants with ALS.

Read the detailed description

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. This trial is designed as a perpetual platform trial. This means that there is a single Master Protocol dictating the conduct of the trial. The HEALEY ALS Platform Trial Master Protocol is registered as NCT04297683.

Once a participant enrolls into the Master Protocol and meets all eligibility criteria, the participant will be eligible to be randomized into any currently enrolling regimen. All participants will have an equal chance of being randomized to any currently enrolling regimen.

If a participant is randomized to Regimen D Pridopidine, the participant will complete a screening visit to assess additional Regimen D eligibility criteria. Once Regimen D eligibility criteria are confirmed, participants will complete a baseline assessment and be randomized in a 3:1 ratio to either active pridopidine or matching placebo.

Regimen D will enroll by invitation, as participants may not choose to enroll in Regimen D. Participants must first enroll into the Master Protocol and be eligible to participate in the Master Protocol before being able to be randomly assigned to Regimen D.

For a list of enrolling sites, please see the HEALEY ALS Platform Trial Master Protocol under NCT04297683.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis

Keywords

  • ALS
  • Placebo-Controlled
  • Double-Blind
  • Regimen Specific Appendix
  • Lou Gehrig's Disease
  • Pridopidine
  • Prilenia Therapeutics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT NCT04297683).

Exclusion criteria

Exclusion Criteria:

  • The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683).

    1. Participants with a confirmed prolonged Fridericia- (QTcF) interval (defined as a QTcF interval of >450 ms for men and >470 ms for women).
    2. Participants with heart disease, clinically significant history of arrhythmia, symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia, or presence of left bundle branch block.
    3. Participants with known history of long QT syndrome or a first degree relative with this condition.
    4. Participants using prohibited medications within the 4 weeks prior to the Regimen Specific Screening Visit, as detailed in section 5.9.
    5. Participants using the following medications at the time of the Regimen Specific Screening Visit:

      1. Nuedexta - at a dosage higher than 20 mg dextromethorphan + 10 mg quinidine BID
      2. Citalopram - at a dosage higher than 20 mg/day
      3. Escitalopram - at a dosage higher than 10 mg/day
    6. Participants with a known allergy to any ingredient of the study intervention (pridopidine, silicified microcrystalline cellulose, and magnesium stearate).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
163 participants (actual)

Study arms

  • Experimental
    Pridopidine

    Pridopidine is administered orally twice daily for 24 weeks.

    Drug: Pridopidine

  • Placebo comparator
    Matching Placebo

    Matching placebo is administered orally twice daily for 24 weeks.

    Drug: Matching Placebo

Interventions

  • Administration: Oral Dose: 45mg twice daily

  • DrugMatching Placebo

    Administration: Oral Dose: one capsule twice daily

06

What researchers measure

Primary outcomes

  1. Disease Progression as Assessed by the ALSFRS-R Total Score

    Change in disease severity over time as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R). Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.

    Time frame: Baseline to 24 Weeks

  2. Mortality Event Rate

    Mortality is defined as death or death equivalent. A participant is determined to meet the criteria of death equivalent if permanent assisted ventilation (PAV) is used for more than 22 hours per day for more than seven days in a row. The rate of mortality was estimated from a Bayesian shared-parametric model that assumed exponentially distributed survival times.

    Time frame: Baseline to 24 Weeks

Secondary outcomes

  1. Change in Bulbar Function in Participants With Bulbar Dysfunction at Baseline

    Change in bulbar function over time in participants with bulbar dysfunction at baseline as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) bulbar subdomain. Each question is scored from 4 (normal) to 0 (no ability), with a maximum total score of 12 and a minimum total score of 0 for the bulbar subdomain. Patients with higher scores have more bulbar function. Participants were classified as having bulbar dysfunction at baseline if their score on the ALSFRS-R bulbar domain (Q1-Q3) score was less than 12.

    Time frame: Baseline to 24 Weeks

  2. Bulbar Function in All Randomized Participants

    Change in bulbar function over time in all randomized participants as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) bulbar subdomain. Each question is scored from 4 (normal) to 0 (no ability), with a maximum total score of 12 and a minimum total score of 0 for the bulbar subdomain. Patients with higher scores have more bulbar function.

    Time frame: Baseline to 24 Weeks

  3. Respiratory Function

    Change in respiratory function over time as measured by Slow Vital Capacity (SVC).

    Time frame: Baseline to 24 Weeks

  4. Bulbar Function in Participants With Rapid Pre-baseline Progression

    Change in bulbar function over time in participants with rapid pre-baseline progression as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) bulbar subdomain. Each question is scored from 4 (normal) to 0 (no ability), with a maximum total score of 12 and a minimum total score of 0 for the bulbar subdomain. Patients with higher scores have more bulbar function. Participants were classified with rapid pre-baseline progression if their change in ALSFRS-R total score between Master Protocol Screening and Regimen Baseline was greater than or equal or 0.75 points per month.

    Time frame: Baseline to 24 Weeks

  5. Time to Bulbar Decline

    Time to first decline of 1-point or greater post baseline in the ALSFRS-R bulbar domain score among all participants. Analysis performed using interval-censored survival analysis. Results presented as median interval (upper \& lower bounded) time to event.

    Time frame: Baseline to 24 Weeks

  6. Muscle Strength

    Change in muscle strength over time as measured isometrically using hand-held dynamometry (HHD).

    Time frame: Baseline to 24 Weeks

  7. Number of Participants That Experienced Death or Death Equivalent

    The number of participants who died or met the criterion for a death equivalent from the date of their baseline visit to the end of the Week 24visit window (generally 175 days after baseline). The death equivalent criterion is use of permanent assisted ventilation (PAV) for more than 22 hours per day for more than 7 days in a row.

    Time frame: Baseline to 24 Weeks

07

Results

Posted Aug 23, 2023

Participant flow

Participant flow — Overall Study
MilestonePridopidineMatching Placebo
Started12042
Completed9638
Not completed244

Outcome measures

PrimaryDisease Progression as Assessed by the ALSFRS-R Total Score

Change in disease severity over time as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R). Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.

Time frame:
Baseline to 24 Weeks
Reported as:
Mean · points per month
Disease Progression as Assessed by the ALSFRS-R Total Score
points per monthPridopidineMatching Placebo
Disease Progression as Assessed by the ALSFRS-R Total Score-0.99 ± 0.077-1.00 ± 0.070
Statistical analysis
  • Pridopidine vs Matching Placebo · Bayesian shared-parameter model · Disease rate ratio: 0.99 · 95% CI 0.801 to 1.207DDR \<1 imply slowing of disease progression by verdiperstat relative to placebo.Note: reported "Confidence Interval" is actually a Bayesian credible interval.
PrimaryMortality Event Rate

Mortality is defined as death or death equivalent. A participant is determined to meet the criteria of death equivalent if permanent assisted ventilation (PAV) is used for more than 22 hours per day for more than seven days in a row. The rate of mortality was estimated from a Bayesian shared-parametric model that assumed exponentially distributed survival times.

Time frame:
Baseline to 24 Weeks
Reported as:
Mean · events per month
Mortality Event Rate
events per monthPridopidineMatching Placebo
Mortality Event Rate0.012 ± 0.00290.012 ± 0.0029
SecondaryChange in Bulbar Function in Participants With Bulbar Dysfunction at Baseline

Change in bulbar function over time in participants with bulbar dysfunction at baseline as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) bulbar subdomain. Each question is scored from 4 (normal) to 0 (no ability), with a maximum total score of 12 and a minimum total score of 0 for the bulbar subdomain. Patients with higher scores have more bulbar function. Participants were classified as having bulbar dysfunction at baseline if their score on the ALSFRS-R bulbar domain (Q1-Q3) score was less than 12.

Time frame:
Baseline to 24 Weeks
Reported as:
Least squares mean · point change from baseline
Change in Bulbar Function in Participants With Bulbar Dysfunction at Baseline
point change from baselinePridopidineMatching Placebo
Change in Bulbar Function in Participants With Bulbar Dysfunction at Baseline-1.78 ± 0.261-1.69 ± 0.210
Statistical analysis
  • Pridopidine vs Matching Placebo · Mixed Models Analysis · p = 0.78 · Median difference (net): -0.09 · 95% CI -0.75 to 0.57Pridopidine 24-week change from baseline relative to placebo 24-week change from baseline.
SecondaryBulbar Function in All Randomized Participants

Change in bulbar function over time in all randomized participants as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) bulbar subdomain. Each question is scored from 4 (normal) to 0 (no ability), with a maximum total score of 12 and a minimum total score of 0 for the bulbar subdomain. Patients with higher scores have more bulbar function.

Time frame:
Baseline to 24 Weeks
Reported as:
Least squares mean · point change from baseline
Bulbar Function in All Randomized Participants
point change from baselinePridopidineMatching Placebo
Bulbar Function in All Randomized Participants-1.16 ± 0.169-1.25 ± 0.141
Statistical analysis
  • Pridopidine vs Matching Placebo · Mixed Models Analysis · p = 0.6594 · Median difference (net): 0.10 · 95% CI -0.33 to 0.52Pridopidine 24-week change from baseline relative to placebo 24-week change from baseline.
SecondaryRespiratory Function

Change in respiratory function over time as measured by Slow Vital Capacity (SVC).

Time frame:
Baseline to 24 Weeks
Reported as:
Least squares mean · percent change
Respiratory Function
percent changePridopidineMatching Placebo
Respiratory Function-8.81 ± 1.351-8.35 ± 1.132
Statistical analysis
  • Pridopidine vs Matching Placebo · Mixed Models Analysis · p = 0.7918 · Mean difference (net): -0.46 · 95% CI -3.89 to 2.96Pridopidine 24-week change from baseline relative to placebo 24-week change from baseline.
SecondaryBulbar Function in Participants With Rapid Pre-baseline Progression

Change in bulbar function over time in participants with rapid pre-baseline progression as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) bulbar subdomain. Each question is scored from 4 (normal) to 0 (no ability), with a maximum total score of 12 and a minimum total score of 0 for the bulbar subdomain. Patients with higher scores have more bulbar function. Participants were classified with rapid pre-baseline progression if their change in ALSFRS-R total score between Master Protocol Screening and Regimen Baseline was greater than or equal or 0.75 points per month.

Time frame:
Baseline to 24 Weeks
Reported as:
Least squares mean · points change from baseline
Bulbar Function in Participants With Rapid Pre-baseline Progression
points change from baselinePridopidineMatching Placebo
Bulbar Function in Participants With Rapid Pre-baseline Progression-1.54 ± 0.297-1.54 ± 0.302
Statistical analysis
  • Pridopidine vs Matching Placebo · Mixed Models Analysis · p = 0.9903 · Median difference (net): 0.01 · 95% CI -0.83 to 0.84Pridopidine 24-week change from baseline relative to placebo 24-week change from baseline.
SecondaryTime to Bulbar Decline

Time to first decline of 1-point or greater post baseline in the ALSFRS-R bulbar domain score among all participants. Analysis performed using interval-censored survival analysis. Results presented as median interval (upper \& lower bounded) time to event.

Time frame:
Baseline to 24 Weeks
Reported as:
Median · days
Time to Bulbar Decline
daysPridopidineMatching Placebo
Lower Bound of Interval84 (53 to 141)66 (56 to 105)
Upper Bound of Interval86 (83 to 141)77 (68 to 115)
Statistical analysis
  • Pridopidine vs Matching Placebo · Regression, Cox · Hazard ratio (hr): 0.93 · 95% CI 0.69 to 1.27Interval censored cox model adjusted for time since symptom onset, pre-baseline change in ALSFRS-R, baseline use of edaravone, riluzole, and neudexta
SecondaryMuscle Strength

Change in muscle strength over time as measured isometrically using hand-held dynamometry (HHD).

Time frame:
Baseline to 24 Weeks
Reported as:
Least squares mean · percent change
Muscle Strength
percent changePridopidineMatching Placebo
Muscle Strength-26.74 ± 2.556-24.97 ± 2.123
Statistical analysis
  • Pridopidine vs Matching Placebo · Mixed Models Analysis · p = 0.5888 · Mean difference (net): -1.78 · 95% CI -8.23 to 4.67Pridopidine 24-week change from baseline relative to placebo 24-week change from baseline.
SecondaryNumber of Participants That Experienced Death or Death Equivalent

The number of participants who died or met the criterion for a death equivalent from the date of their baseline visit to the end of the Week 24visit window (generally 175 days after baseline). The death equivalent criterion is use of permanent assisted ventilation (PAV) for more than 22 hours per day for more than 7 days in a row.

Time frame:
Baseline to 24 Weeks
Reported as:
Count of participants · Participants
Number of Participants That Experienced Death or Death Equivalent
ParticipantsPridopidineMatching Placebo
Number of Participants That Experienced Death or Death Equivalent56
Statistical analysis
  • Pridopidine vs Matching Placebo · Log Rank · p = 0.9690

Adverse events

Collected over Up to 35 weeks after participant signed Master Protocol consent.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pridopidine2/120 (1.7%)16/121 (13.2%)106/121 (87.6%)
Matching Placebo0/42 (0%)3/41 (7.3%)37/41 (90.2%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventPridopidineMatching Placebo
Respiratory failureRespiratory, thoracic and mediastinal disorders3/1211/41
Ankle fractureInjury, poisoning and procedural complications0/1211/41
SepsisInfections and infestations0/1211/41
Amyotrophic lateral sclerosisNervous system disorders2/1210/41
SyncopeNervous system disorders2/1210/41
Atrial fibrillationCardiac disorders2/1210/41
Cerebellar strokeNervous system disorders1/1210/41
Ischaemic strokeNervous system disorders1/1210/41
PresyncopeNervous system disorders1/1210/41
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/1210/41
Most frequent other events
Showing 10 of 29
Most frequent other events
EventPridopidineMatching Placebo
Muscular weaknessNervous system disorders29/12113/41
FallInjury, poisoning and procedural complications34/12112/41
NeuromyopathyNervous system disorders24/1213/41
ConstipationGastrointestinal disorders14/1218/41
DiarrhoeaGastrointestinal disorders15/1214/41
NauseaGastrointestinal disorders15/1213/41
DysphagiaGastrointestinal disorders13/1215/41
FatigueGeneral disorders12/1215/41
COVID-19Infections and infestations12/1214/41
DysarthriaNervous system disorders10/1214/41

Baseline characteristics

Baseline Analysis Population includes only placebo participants from the Regimen D Efficacy Regimen Only (ERO) sample; shared placebo participants from other regimens are not included in the Baseline Analysis Population.

Age, Continuous
Age, Continuous(years)PridopidineMatching PlaceboTotal
Mean57.9 ± 10.1057.1 ± 9.8657.7 ± 10.01
Sex: Female, Male
Sex: Female, Male(Participants)PridopidineMatching PlaceboTotal
Female48957
Male7233105
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PridopidineMatching PlaceboTotal
Hispanic or Latino11112
Not Hispanic or Latino10741148
Unknown or Not Reported202
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PridopidineMatching PlaceboTotal
American Indian or Alaska Native000
Asian516
Native Hawaiian or Other Pacific Islander000
Black or African American729
White10539144
More than one race101
Unknown or Not Reported202
El Escorial Diagnosis
El Escorial Diagnosis(Participants)PridopidineMatching PlaceboTotal
Clinically Definite ALS501868
Clinically Probable ALS401252
Clinically Probable ALS - Laboratory Supported22527
Clinically Possible ALS8715
ALS Onset Location
ALS Onset Location(Participants)PridopidineMatching PlaceboTotal
Axial123
Bulbar231033
Generalized202
Limb9330123
Multiple101
Baseline Edaravone Use Flag
Baseline Edaravone Use Flag(Participants)PridopidineMatching PlaceboTotal
No9232124
Yes281038
Baseline Riluzole Use Flag
Baseline Riluzole Use Flag(Participants)PridopidineMatching PlaceboTotal
No30939
Yes9033123

10 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Healey Center for ALS at Mass General
    Boston, Massachusetts 02114, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Jul 2022, 18 months.

Results were first posted in Aug 2023, 1 year 1 month after primary completion.

Of 22 phase 2/3 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 109. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2020
First posted
Nov 4, 2020
StartActual
Dec 18, 2020
Primary completionActual
Jul 14, 2022
CompletionActual
Jul 14, 2022
Results first posted
Aug 23, 2023
Last update
Aug 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04615923
Lead sponsor
Merit E. Cudkowicz, MD
Collaborators
Prilenia
Responsible party
Merit E. Cudkowicz, MD (Chief, Neurology Department, Massachusetts General Hospital) — Sponsor-investigator
First posted
Nov 4, 2020
Start date
Dec 18, 2020
Primary completion
Jul 14, 2022
Completion
Jul 14, 2022
Results posted
Aug 23, 2023
Last update
Aug 23, 2023

Study contacts

Merit Cudkowicz, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pridopidine

Start the discussion